Repare Therapeutics (RPTX) IPO Opens 60% Higher

Today's IPO for Repare Therapeutics Inc. (NASDAQ: RPTX) opened for trading at $32.05 after pricing its upsized initial public offering of 11,000,000 of its common shares at a public offering price of $20.00 per share.

In addition, Repare has granted the underwriters a 30-day option to purchase up to 1,650,000 additional common shares at the initial public offering price, less the underwriting commissions.

Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler & Co. are acting as joint book-running managers for the offering.

Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs.

You May Also Be Interested In

• YPF Energía Eléctrica S.A. files for proposed NYSE IPO
• Columbus Circle Capital Corp. III closes $230M IPO on Nasdaq
• NextCure and Avere to merge, targeting oral IL-23 therapy